Covered recipient · General Payments record
SEEMA ALI BHAT
Allopathic & Osteopathic Physicians Internal Medicine Hematology
General Payments · PY2018–2024
$56,589.40
- Reported across 73 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $8,705.00 | 4 |
| Travel and Lodging | $1,066.14 | 3 |
| Food and Beverage | $363.03 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $5,327.50 | 3 |
| ABBVIE INC. | $4,728.67 | 7 |
| BeiGene USA, Inc. | $78.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $131.29 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321808 | CMS |
| ABBVIE INC. | $365.12 | 05/31/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104177410 | CMS |
| ABBVIE INC. | $590.14 | 06/01/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104177412 | CMS |
| ABBVIE INC. | $110.88 | 09/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104177414 | CMS |
| ABBVIE INC. | $93.74 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321810 | CMS |
| ABBVIE INC. | $937.50 | 12/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131925 | CMS |
| ABBVIE INC. | $2,500.00 | 12/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103131927 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,397.50 | 10/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104317838 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104452744 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,870.00 | 12/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104654733 | CMS |
| BeiGene USA, Inc. | $78.00 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120860975 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.